Experts Debate EGFR-Mutant NSCLC Monotherapy vs Combination
At WCLC 2026, thoracic oncologists discussed whether any patients with EGFR-mutant non-small cell lung cancer still need single-agent therapy, weighing toxicity and data from the PALOMA-2 trial.
At the 2026 World Conference on Lung Cancer, thoracic oncologists revisited a central question in treating EGFR-mutant non-small cell lung cancer: whether single-agent therapy remains a valid option for any patient. The discussion weighed the clinical trade-off between treatment efficacy and cumulative toxicity, with the PALOMA-2 trial providing key comparative data. While combination regimens have expanded options, the debate acknowledged that monotherapy may still serve specific patient subgroups, though consensus was not reached.
The conversation reflects a broader shift in lung cancer care toward personalized, sequenced treatment strategies. As targeted therapies evolve, clinicians increasingly balance molecular precision against quality-of-life concerns, particularly for patients who may tolerate less intensive regimens. The PALOMA-2 findings appear central to informing these decisions, though the full implications for clinical practice remain under discussion.
This debate could shape treatment guidelines for thousands of lung cancer patients worldwide, influencing whether they receive simpler or more intensive regimens. Clinicians may face harder conversations about toxicity versus survival benefit, while patients could gain more nuanced options tailored to their tolerance and disease stage. The outcome may also affect healthcare costs and resource allocation, as combination therapies often carry higher price tags. Ultimately, this discussion signals a maturing field where treatment choices are increasingly individualized.